Literature DB >> 10784061

Optimal insulin treatment in syngeneic islet transplantation.

J F Merino1, V Nacher, M Raurell, M Biarnés, J Soler, E Montanya.   

Abstract

Insulin-induced normoglycemia has shown to have a beneficial effect on the outcome of pancreatic islets transplanted to diabetic recipients. The aim of the study was to identify the insulin treatment that can maximize its beneficial effect on islet transplants. Six groups of streptozotocin diabetic C57Bl/6 mice were transplanted (Tx) with 100 syngeneic islets, an insufficient beta cell mass to restore normoglycemia, and were treated with insulin as follows: group 1 (n = 9): from day 10 before Tx to day 14 after Tx; group 2 (n = 11): from day 6 before Tx to Tx day; group 3 (n = 11): from Tx day to day 6 after Tx; group 4 (n = 7): from Tx day to day 14 after Tx; group 5 (n = 8): from day 10 to day 24 after Tx; group 6 (n = 18): Tx mice were not treated with insulin. Sixty days after Tx, normoglycemia was achieved in 100% of mice in groups 1, 4, and 5, in 73% of mice in group 2, and in only 45% and 33% of mice in groups 3 and 6, respectively (p < 0.01). Intraperitoneal glucose tolerance, determined only in normoglycemic mice, was similar in groups 1, 2, 4, and normal controls. In contrast, normoglycemic mice from groups 3, 5, and 6, exposed to more severe and prolonged hyperglycemia after Tx, showed higher glucose values after glucose injection, suggesting that hyperglycemia had a long-lasting deleterious effect on transplanted beta cell function. The initially transplanted beta cell mass was maintained in the grafts of normoglycemic mice, but was severely reduced in hyperglycemic mice. Transplanted beta cell mass was similar in normoglycemic groups with normal or impaired glucose tolerance, indicating that impaired glucose tolerance was not due to reduced beta cell mass. In summary, the beneficial effect of insulin-induced normoglycemia on transplanted islets was maximal when insulin treatment was maintained the initial 14 days after transplantation. Exposure to sustained hyperglycemia initially after transplantation had a long-lasting deleterious effect on transplanted islets.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10784061     DOI: 10.1177/096368970000900102

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  8 in total

1.  Near-euglycemia can be achieved safely in pediatric total pancreatectomy islet autotransplant recipients using an adapted intravenous insulin infusion protocol.

Authors:  Gregory P Forlenza; Srinath Chinnakotla; Sarah J Schwarzenberg; Marie Cook; David M Radosevich; Carol Manchester; Sameer Gupta; Brandon Nathan; Melena D Bellin
Journal:  Diabetes Technol Ther       Date:  2014-07-28       Impact factor: 6.118

2.  Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment.

Authors:  A King; J Lock; G Xu; S Bonner-Weir; G C Weir
Journal:  Diabetologia       Date:  2005-08-23       Impact factor: 10.122

3.  Human islet cell implants in a nude rat model of diabetes survive better in omentum than in liver with a positive influence of beta cell number and purity.

Authors:  D Jacobs-Tulleneers-Thevissen; K Bartholomeus; K Suenens; I Vermeulen; Z Ling; K H Hellemans; P In't Veld; M Pipeleers-Marichal; D Pipeleers
Journal:  Diabetologia       Date:  2010-04-16       Impact factor: 10.122

Review 4.  Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions.

Authors:  Michael R Rickels; R Paul Robertson
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

5.  Generation of functional insulin-producing cells from mouse embryonic stem cells through 804G cell-derived extracellular matrix and protein transduction of transcription factors.

Authors:  Taku Kaitsuka; Hirofumi Noguchi; Nobuaki Shiraki; Takuya Kubo; Fan-Yan Wei; Farzana Hakim; Shoen Kume; Kazuhito Tomizawa
Journal:  Stem Cells Transl Med       Date:  2013-11-29       Impact factor: 6.940

6.  Successful Application of Closed-Loop Artificial Pancreas Therapy After Islet Autotransplantation.

Authors:  G P Forlenza; B M Nathan; A M Moran; T B Dunn; G J Beilman; T L Pruett; M D Bellin
Journal:  Am J Transplant       Date:  2015-11-20       Impact factor: 8.086

7.  On the management of hyperglycaemia in critically ill patients undergoing surgery.

Authors:  Iakovos Nomikos; Maria Kyriazi; Dimitra Vamvakopoulou; Andreas Sidiropoulos; Athanasios Apostolou; Aspasia Kyritsaka; Evangelos Athanassiou; Nikolaos C Vamvakopoulos
Journal:  J Clin Med Res       Date:  2012-07-20

8.  A Model for Human Islet Transplantation to Immunodeficient Streptozotocin-Induced Diabetic Mice.

Authors:  Elisabet Estil Les; Noèlia Téllez; Montserrat Nacher; Eduard Montanya
Journal:  Cell Transplant       Date:  2018-10-01       Impact factor: 4.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.